Updates in IPF and Related Fibrotic Lung Diseases: Expanding Applications f...

Event Information

Share this event

Date and Time



San Antonio Marriott Rivercenter

101 Bowie Street

Salon ABF, Level 3

San Antonio, TX 78205

View Map

Event description


This program is intended for American College of Chest Physicians 2018 Meeting attendees only.

Activity Chair

Steven D. Nathan, MD
Medical Director Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Professor of Medicine, Virginia Commonwealth University - Inova Fairfax Campus
Falls Church, VA


Kristin B. Highland, MD, MSCR
Staff Physician
Cleveland Clinic
Cleveland, OH


Idiopathic pulmonary fibrosis (IPF) is a specific form of progressive fibrosing interstitial lung disease (ILD), with a median survival of 2 to 5 years from the time of diagnosis. Two therapeutics recently approved by the US Food and Drug Administration (FDA) have demonstrated delayed pulmonary decline in patients with IPF further highlighting the need for early diagnosis and timely initiation of therapy. These two FDA-approved IPF therapies are also currently under investigation for the treatment of other fibrotic lung diseases, including systemic sclerosis-related ILD, progressive fibrosing ILD, and usual interstitial pneumonia. In this live satellite symposium, experts in the field will discuss emerging strategies for the timely and accurate identification of patients with fibrotic lung disease, as well as evaluate the latest clinical data on the expanding applications of current IPF therapies.


5:45 AM
Registration and Breakfast

6:15 AM
Introduction and Pretest
Steven D. Nathan, MD

6:20 AM
Timely and Accurate Identification of Patients with Fibrotic Lung Disease
Steven D. Nathan, MD

6:45 AM
Expanding Applications for Current IPF Therapies
Kristin B. Highland, MD, MSCR

7:05 AM
Posttest and Question & Answer

7:15 AM

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Examine emerging evidence regarding biomarkers for the diagnosis, prognosis, and prediction of treatment response for patients with IPF.

  • Assess the latest clinical evidence regarding emerging applications for new IPF treatments, including combination approaches and related fibrotic lung diseases.

  • Implement treatment for patients with fibrotic lung disease in accordance with the latest clinical evidence.

Target Audience

The intended audience for this activity is pulmonologists, internists, and other health care professionals involved in the treatment of patients with IPF.

This continuing medical education activity is provided by Vindico Medical Education.

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support,all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.

Share with friends

Date and Time


San Antonio Marriott Rivercenter

101 Bowie Street

Salon ABF, Level 3

San Antonio, TX 78205

View Map

Save This Event

Event Saved